Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Magnus Althage

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Journal of Medicinal Chemistry|March 19, 2024
Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) AgonistsKenneth L Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, et al.
Molecular Therapy. Advances|May 15, 2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humansErik Ryberg, Fredrik Bergström, Sebastian Sten, et al.
JCI Insight|June 21, 2019
Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic miceMariam Aghajan, Sheri L Booten, Magnus Althage, et al.
JHLT Open|August 1, 2025
Ex situ heart perfusion: A novel platform to test cardiovascular therapeutics in human heartsJohn Onsy Louca, Magnus Althage, Marco Öchsner, et al.
BMC Biology|January 17, 2019
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse modelAlba Carreras, Luna Simona Pane, Roberto Nitsch, et al.
Cardiovascular Research|March 4, 2025
A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunctionMonika Papworth, Spoorthy Kulkarni, Madeleine Antonsson, et al.
Journal of Medicinal Chemistry|March 19, 2024
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart FailureKenneth L Granberg, Shigeki Sakamaki, Niklas Larsson, et al.
Nature Metabolism|February 20, 2020
IDOL regulates systemic energy balance through control of neuronal VLDLR expressionStephen D Lee, Christina Priest, Mikael Bjursell, et al.
The Journal of Biological Chemistry|March 6, 2020
Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain functionJenny Sandmark, Anna Tigerström, Tomas Akerud, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Journal of Medicinal Chemistry|March 19, 2024
Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) AgonistsKenneth L Granberg, Shigeki Sakamaki, Ryuichi Fuchigami, et al.
Molecular Therapy. Advances|May 15, 2026
The first oral relaxin receptor RXFP1 agonist for heart failure treatment: Translational studies from non-human primates to humansErik Ryberg, Fredrik Bergström, Sebastian Sten, et al.
JCI Insight|June 21, 2019
Antisense oligonucleotide treatment ameliorates IFN-γ-induced proteinuria in APOL1-transgenic miceMariam Aghajan, Sheri L Booten, Magnus Althage, et al.
JHLT Open|August 1, 2025
Ex situ heart perfusion: A novel platform to test cardiovascular therapeutics in human heartsJohn Onsy Louca, Magnus Althage, Marco Öchsner, et al.
BMC Biology|January 17, 2019
In vivo genome and base editing of a human PCSK9 knock-in hypercholesterolemic mouse modelAlba Carreras, Luna Simona Pane, Roberto Nitsch, et al.
Cardiovascular Research|March 4, 2025
A novel long-acting relaxin-2 fusion, AZD3427, improves cardiac performance in non-human primates with cardiac dysfunctionMonika Papworth, Spoorthy Kulkarni, Madeleine Antonsson, et al.
Journal of Medicinal Chemistry|March 19, 2024
Discovery of Clinical Candidate AZD5462, a Selective Oral Allosteric RXFP1 Agonist for Treatment of Heart FailureKenneth L Granberg, Shigeki Sakamaki, Niklas Larsson, et al.
Nature Metabolism|February 20, 2020
IDOL regulates systemic energy balance through control of neuronal VLDLR expressionStephen D Lee, Christina Priest, Mikael Bjursell, et al.
The Journal of Biological Chemistry|March 6, 2020
Identification and analyses of inhibitors targeting apolipoprotein(a) kringle domains KIV-7, KIV-10, and KV provide insight into kringle domain functionJenny Sandmark, Anna Tigerström, Tomas Akerud, et al.
Pageof 3